Cargando…

Identification of a Peptide for Systemic Brain Delivery of a Morpholino Oligonucleotide in Mouse Models of Spinal Muscular Atrophy

Splice-switching antisense oligonucleotides are emerging treatments for neuromuscular diseases, with several splice-switching oligonucleotides (SSOs) currently undergoing clinical trials such as for Duchenne muscular dystrophy (DMD) and spinal muscular atrophy (SMA). However, the development of syst...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shabanpoor, Fazel, Hammond, Suzan M, Abendroth, Frank, Hazell, Gareth, Wood, Matthew J.A., Gait, Michael J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Mary Ann Liebert, Inc. 2017
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5467147/ https://www.ncbi.nlm.nih.gov/pubmed/28118087 http://dx.doi.org/10.1089/nat.2016.0652

Ejemplares similares

Development of a general methodology for labelling peptide–morpholino oligonucleotide conjugates using alkyne–azide click chemistry
por: Shabanpoor, Fazel, et al.
Publicado: (2013)

Antibody-oligonucleotide conjugate achieves CNS delivery in animal models for spinal muscular atrophy
por: Hammond, Suzan M., et al.
Publicado: (2022)

Peptide Nanoparticle Delivery of Charge-Neutral Splice-Switching Morpholino Oligonucleotides
por: Järver, Peter, et al.
Publicado: (2015)

Bi-specific splice-switching PMO oligonucleotides conjugated via a single peptide active in a mouse model of Duchenne muscular dystrophy
por: Shabanpoor, Fazel, et al.
Publicado: (2015)

Combining multiomics and drug perturbation profiles to identify muscle-specific treatments for spinal muscular atrophy
por: Meijboom, Katharina E., et al.
Publicado: (2021)

Scavenger Receptor Class A1 Mediates Uptake of Morpholino Antisense Oligonucleotide into Dystrophic Skeletal Muscle
por: Miyatake, Shouta, et al.
Publicado: (2019)

Delivery of therapeutic oligonucleotides with cell penetrating peptides()
por: Boisguérin, Prisca, et al.
Publicado: (2015)

Peptide-mediated Cell and In Vivo Delivery of Antisense Oligonucleotides and siRNA
por: Järver, Peter, et al.
Publicado: (2012)

Investigation of New Morpholino Oligomers to Increase Survival Motor Neuron Protein Levels in Spinal Muscular Atrophy
por: Ramirez, Agnese, et al.
Publicado: (2018)

Cell-Penetrating Peptide Conjugates of Steric Blocking Oligonucleotides as Therapeutics for Neuromuscular Diseases from a Historical Perspective to Current Prospects of Treatment
por: Gait, Michael J., et al.
Publicado: (2019)

Enhanced delivery of peptide-morpholino oligonucleotides with a small molecule to correct splicing defects in the lung
por: Dang, Yan, et al.
Publicado: (2021)

Dual Myostatin and Dystrophin Exon Skipping by Morpholino Nucleic Acid Oligomers Conjugated to a Cell-penetrating Peptide Is a Promising Therapeutic Strategy for the Treatment of Duchenne Muscular Dystrophy
por: Malerba, Alberto, et al.
Publicado: (2012)

Modular Synthesis of Trifunctional Peptide-oligonucleotide Conjugates via Native Chemical Ligation
por: Dastpeyman, Mohadeseh, et al.
Publicado: (2021)

Pip6-PMO, A New Generation of Peptide-oligonucleotide Conjugates With Improved Cardiac Exon Skipping Activity for DMD Treatment
por: Betts, Corinne, et al.
Publicado: (2012)

Splice-Switching Therapy for Spinal Muscular Atrophy
por: Meijboom, Katharina E., et al.
Publicado: (2017)

Aminoglycoside Enhances the Delivery of Antisense Morpholino Oligonucleotides In Vitro and in mdx Mice
por: Wang, Mingxing, et al.
Publicado: (2019)

Interventions Targeting Glucocorticoid-Krüppel-like Factor 15-Branched-Chain Amino Acid Signaling Improve Disease Phenotypes in Spinal Muscular Atrophy Mice
por: Walter, Lisa M., et al.
Publicado: (2018)

Saponins as Natural Adjuvant for Antisense Morpholino Oligonucleotides Delivery In Vitro and in mdx Mice
por: Wang, Mingxing, et al.
Publicado: (2018)

Myoblasts and macrophages are required for therapeutic morpholino antisense oligonucleotide delivery to dystrophic muscle
por: Novak, James S., et al.
Publicado: (2017)

Polyquaternium-mediated delivery of morpholino oligonucleotides for exon-skipping in vitro and in mdx mice
por: Wang, Mingxing, et al.
Publicado: (2017)

AMOD: a morpholino oligonucleotide selection tool
por: Klee, Eric W., et al.
Publicado: (2005)

Dysregulation of Tweak and Fn14 in skeletal muscle of spinal muscular atrophy mice
por: Meijboom, Katharina E., et al.
Publicado: (2022)

Evaluation of Amphiphilic Peptide Modified Antisense Morpholino Oligonucleotides In Vitro and in Dystrophic mdx Mice
por: Wang, Mingxing, et al.
Publicado: (2017)

Myostatin inhibition in combination with antisense oligonucleotide therapy improves outcomes in spinal muscular atrophy
por: Zhou, Haiyan, et al.
Publicado: (2020)

Rapid Screening of Gene Function by Systemic Delivery of Morpholino Oligonucleotides to Live Mouse Embryos
por: McClelland, Kathryn S., et al.
Publicado: (2015)

Morpholino antisense oligonucleotides: tools for investigating vertebrate development
por: Corey, David R, et al.
Publicado: (2001)

Nitroreductase-Activatable Morpholino Oligonucleotides for in Vivo Gene Silencing
por: Yamazoe, Sayumi, et al.
Publicado: (2014)

A Short Antisense Oligonucleotide Ameliorates Symptoms of Severe Mouse Models of Spinal Muscular Atrophy
por: Keil, Jeffrey M, et al.
Publicado: (2014)

Light modulation ameliorates expression of circadian genes and disease progression in spinal muscular atrophy mice
por: Walter, Lisa M, et al.
Publicado: (2018)

PepFect 14, a novel cell-penetrating peptide for oligonucleotide delivery in solution and as solid formulation
por: Ezzat, Kariem, et al.
Publicado: (2011)

Spinal muscular atrophy
por: D'Amico, Adele, et al.
Publicado: (2011)

Cationic polyelectrolyte-mediated delivery of antisense morpholino oligonucleotides for exon-skipping in vitro and in mdx mice
por: Wang, Mingxing, et al.
Publicado: (2015)

Author Correction: Myoblasts and macrophages are required for therapeutic morpholino antisense oligonucleotide delivery to dystrophic muscle
por: Novak, James S., et al.
Publicado: (2018)

Author Correction: Myoblasts and macrophages are required for therapeutic morpholino antisense oligonucleotide delivery to dystrophic muscle
por: Novak, James S., et al.
Publicado: (2018)

Targeting the 5′ untranslated region of SMN2 as a therapeutic strategy for spinal muscular atrophy
por: Winkelsas, Audrey M., et al.
Publicado: (2021)

Defining Synphenotype Groups in Xenopus tropicalis by Use of Antisense Morpholino Oligonucleotides
por: Rana, Amer Ahmed, et al.
Publicado: (2006)

A Semi‐Mechanistic Population Pharmacokinetic Model of Nusinersen: An Antisense Oligonucleotide for the Treatment of Spinal Muscular Atrophy
por: Biliouris, Konstantinos, et al.
Publicado: (2018)

Synthesis of Backbone-Modified Morpholino Oligonucleotides Using Phosphoramidite Chemistry
por: Paul, Sibasish, et al.
Publicado: (2023)

Targeted Delivery of FLT-Morpholino Using Cyclic RGD Peptide
por: Uehara, Hironori, et al.
Publicado: (2017)

Solid-Phase Synthesis of Difficult Purine-Rich PNAs through Selective Hmb Incorporation: Application to the Total Synthesis of Cell Penetrating Peptide-PNAs
por: Tailhades, Julien, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_7btcdcclsmttbuj0k37bgth9c0